
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines demonstrates a positive financial outlook with anticipated revenue growth from the launches of zanidatamab and tarlatamab in China, alongside established products such as Xgeva and Blincyto, contributing to a strong revenue stream. The company’s flagship drug, Brukinsa, which commands significant market preference over competitor BTK inhibitors, is projected to reach peak sales of approximately $7.1 billion, further supported by robust prescription volume and seasonal sales patterns. Additionally, the emergence of next-generation therapies like sonrotoclaxis, poised to outperform existing treatments, is expected to bolster BeOne’s revenue further in the long term.
Bears say
BeOne Medicines faces a negative outlook primarily due to slower-than-expected product uptake and challenges with its pipeline programs, particularly failures in solid tumor initiatives and differentiation of other candidates that could negatively impact revenue growth. Additionally, the company's reliance on Brukinsa, which constitutes over 60% of its revenue, poses a significant risk, especially given past revenue misses and concerns about enrollment and commercialization delays. Furthermore, geopolitical risks associated with its Chinese origins, high cash burn without guaranteed marketable outcomes, and the crowded competitive landscape in hematologic oncology compound the financial uncertainties surrounding BeOne's future performance.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares